Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-96673 in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04860466Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of CC-96673 in non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Primary endpoints: Incidence of Adverse Events (AEs), Dose-limiting toxicity up to 18 months and 1 more. Started Jan 2022; status: terminated.
02
Drugs
CC-96673
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04860466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860466.